Pharma stocks fall after new drug price probe in USUS politicians from the resurgent Democratic party have launched a probe into “unsustainable” drug price rises, prompting their Share XPharma stocks fall after new drug price probe in UShttps://pharmaphorum.com/news/pharma-stocks-fall-after-new-drug-price-probe-in-us/
Democrats escalate US war on drug pricingIt was the newly-empowered Democrats’ turn to take on pharma drug pricing in the US this week, as Share XDemocrats escalate US war on drug pricinghttps://pharmaphorum.com/news/democrats-escalate-us-war-drug-pricing/
NICE rejects Novartis’ migraine prevention drug AimovigSome migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are Share XNICE rejects Novartis’ migraine prevention drug Aimovighttps://pharmaphorum.com/news/nice-rejects-novartis-migraine-prevention-drug-aimovig/
Novartis’ sickle cell drug gets Breakthrough Therapy designationThe FDA has granted Breakthrough Therapy designation to Novartis’ crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in Share XNovartis’ sickle cell drug gets Breakthrough Therapy designationhttps://pharmaphorum.com/news/novartis-sickle-cell-drug-gets-breakthrough-therapy-designation/
NICE broadens approval for AstraZeneca’s severe asthma drugAstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – Share XNICE broadens approval for AstraZeneca’s severe asthma drughttps://pharmaphorum.com/news/nice-broadens-approval-for-astrazenecas-severe-asthma-drug/
Trump’s war on drug pricing looks set to continueShrugging off warnings from president Donald Trump, pharma companies have announced US price hikes on more than 250 Share XTrump’s war on drug pricing looks set to continuehttps://pharmaphorum.com/market-access-2/trumps-war-on-drug-pricing-looks-set-to-continue/
Praluent not worth the price, finds studySanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent Share XPraluent not worth the price, finds studyhttps://pharmaphorum.com/news/praluent-not-worth-the-price-finds-study/
BioXcel’s agitation drug gets FDA Fast TrackThe FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting Share XBioXcel’s agitation drug gets FDA Fast Trackhttps://pharmaphorum.com/news/bioxcels-agitation-drug-gets-fda-fast-track/
Teva and Neos settle over Cotempla patent disputeTeva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over Share XTeva and Neos settle over Cotempla patent disputehttps://pharmaphorum.com/news/teva-and-neos-settle-over-cotempla-patent-dispute/
